$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny

$alny Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000117867024000008 Filed on February 15, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$494.3M	$439.7M	$1.828B
YoY Change	54.82%	31.25%	76.23%
Cost Of Revenue	$54.61M	$85.86M	$268.2M
YoY Change	31.81%	67.48%	91.35%
Gross Profit	$439.7M	$353.9M	$1.560B
YoY Change	58.25%	24.7%	73.87%
Gross Profit Margin	88.95%	80.47%	85.33%
Selling, General & Admin	$210.8M	$198.1M	$795.6M
YoY Change	14.78%	-5.81%	3.24%
% of Gross Profit	47.94%	55.99%	51.0%
Research & Development	$261.0M	$272.1M	$1.004B
YoY Change	13.2%	3.86%	13.75%
% of Gross Profit	59.35%	76.91%	64.38%
Depreciation & Amortization	$13.52M	$13.45M	$51.60M
YoY Change	-3.9%	-5.99%	31.97%
% of Gross Profit	3.07%	3.8%	3.31%
Operating Expenses	$471.8M	$470.3M	$1.800B
YoY Change	13.9%	-0.45%	8.85%
Operating Profit	-$43.44M	-$116.4M	-$282.2M
YoY Change	-71.01%	-38.28%	-64.06%
Interest Expense	$35.25M	-$23.27M	$121.2M
YoY Change	21.75%	-29.33%	-22.28%
% of Operating Profit
Other Income/Expense, Net	-$20.15M	$1.984M	-$151.3M
YoY Change	-10.65%	-86.33%	-55.74%
Pretax Income	-$63.59M	-$137.7M	-$433.5M
YoY Change	-63.11%	-33.49%	-61.53%
Income Tax	$2.348M	$183.0K	$6.700M
% Of Pretax Income
Net Earnings	-$65.94M	-$137.9M	-$440.2M
YoY Change	-62.13%	-33.55%	-61.08%
Net Earnings / Revenue	-13.34%	-31.35%	-24.08%
Basic Earnings Per Share	-$0.52		-$3.52
Diluted Earnings Per Share	-$0.52	-$1.10	-$3.52
COMMON SHARES
Basic Shares Outstanding	125.9M shares	125.5M shares	124.9M shares
Diluted Shares Outstanding	126.1M shares		124.9M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.360B	$2.428B	$2.439B
YoY Change	15.41%	12.19%	11.27%
Cash & Equivalents	$681.9M	$812.7M	$812.7M
Short-Term Investments	$1.678B	$1.616B	$1.627B
Other Short-Term Assets	$137.0M	$126.4M	$126.4M
YoY Change	15.06%	-4.92%	-4.92%
Inventory	$93.99M	$89.15M	$89.15M
Prepaid Expenses
Receivables	$321.4M	$327.8M	$228.2M
Other Receivables	$240.0M	$99.58M	$99.58M
Total Short-Term Assets	$2.989B	$2.983B	$2.983B
YoY Change	17.61%	10.79%	10.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$523.5M	$526.1M	$725.8M
YoY Change	0.08%	0.49%	-1.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$67.46M	$72.00M	$121.4M
YoY Change	6.32%	8.94%	5.12%
Total Long-Term Assets	$835.8M	$847.2M	$847.2M
YoY Change	-1.78%	-0.81%	-0.81%
TOTAL ASSETS
Total Short-Term Assets	$2.989B	$2.983B	$2.983B
Total Long-Term Assets	$835.8M	$847.2M	$847.2M
Total Assets	$3.824B	$3.830B	$3.830B
YoY Change	12.75%	7.99%	7.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$78.15M	$55.52M	$55.52M
YoY Change	25.57%	-43.4%	-43.4%
Accrued Expenses	$698.9M	$713.0M	$754.5M
YoY Change	37.41%	30.72%	28.45%
Deferred Revenue	$76.85M	$102.8M
YoY Change	114.7%	144.04%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$941.7M	$967.8M	$967.8M
YoY Change	39.85%	26.03%	26.03%
LONG-TERM LIABILITIES
Long-Term Debt	$1.022B	$1.021B	$1.021B
YoY Change	0.38%	0.38%	0.38%
Other Long-Term Liabilities	$320.0M	$308.4M	$2.062B
YoY Change	42.82%	45.09%	7.41%
Total Long-Term Liabilities	$320.0M	$308.4M	$3.083B
YoY Change	42.82%	45.09%	4.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$941.7M	$967.8M	$967.8M
Total Long-Term Liabilities	$320.0M	$308.4M	$3.083B
Total Liabilities	$4.044B	$4.051B	$4.051B
YoY Change	10.75%	9.34%	9.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$7.076B	-$7.010B
YoY Change	4.92%	6.7%
Common Stock	$6.883B	$6.811B
YoY Change	5.52%	5.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$219.3M	-$220.6M	-$220.6M
YoY Change
Total Liabilities & Shareholders Equity	$3.824B	$3.830B	$3.830B
YoY Change	12.75%	7.99%	7.99%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$65.94M	-$137.9M	-$440.2M
YoY Change	-62.13%	-33.55%	-61.08%
Depreciation, Depletion And Amortization	$13.52M	$13.45M	$51.60M
YoY Change	-3.9%	-5.99%	31.97%
Cash From Operating Activities	-$81.52M	-$29.84M	$104.2M
YoY Change	-51.03%	-77.39%	-119.24%
INVESTING ACTIVITIES
Capital Expenditures	$12.97M	$15.31M	$62.21M
YoY Change	-6.61%	-29.23%	-13.67%
Acquisitions
YoY Change
Other Investing Activities	-$54.65M	-$225.3M	$4.438M
YoY Change		90.52%	-5.45%
Cash From Investing Activities	-$67.62M	-$240.7M	-$336.4M
YoY Change	-11.28%	72.0%	-298.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$28.91M	39.23M	$172.1M
YoY Change	-37.65%	-38.16%	-59.57%
NET CHANGE
Cash From Operating Activities	-$81.52M	-29.84M	$104.2M
Cash From Investing Activities	-$67.62M	-240.7M	-$336.4M
Cash From Financing Activities	$28.91M	39.23M	$172.1M
Net Change In Cash	-$130.2M	-231.3M	-$53.67M
YoY Change	-32.95%	10.94%	-215.66%
FREE CASH FLOW
Cash From Operating Activities	-$81.52M	-$29.84M	$104.2M
Capital Expenditures	$12.97M	$15.31M	$62.21M
Free Cash Flow	-$94.49M	-$45.15M	$41.95M
YoY Change	-47.61%	-70.6%	-106.84%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	us-gaap	Interest Expense InterestExpense	143021000	usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001178670
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q4	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2022Q4	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2022	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense
CY2023	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36407
CY2023	dei	Entity Registrant Name EntityRegistrantName	ALNYLAM PHARMACEUTICALS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0602661
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	675 West Kendall Street
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Henri A. Termeer Square
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
CY2023	dei	City Area Code CityAreaCode	617
CY2023	dei	Local Phone Number LocalPhoneNumber	551-8200
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
CY2023	dei	Trading Symbol TradingSymbol	ALNY
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	23650000000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	125945793	shares
CY2023	dei	Auditor Firm AuditorFirmId	238
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	812688000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	866394000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1615516000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1297890000	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	11178000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	28122000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	327787000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	237963000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	89146000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	128962000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	126382000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	132916000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	2982697000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2692247000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	526057000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	523494000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	199732000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	215136000	usd
CY2023Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	49391000	usd
CY2022Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	49390000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	72003000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	66092000	usd
CY2023Q4	us-gaap	Assets Assets	3829880000	usd
CY2022Q4	us-gaap	Assets Assets	3546359000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	55519000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	98094000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	713013000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	545460000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	41510000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	41967000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	102753000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	42105000	usd
CY2023Q4	alny	Royalty Liability Current RoyaltyLiabilityCurrent	54991000	usd
CY2022Q4	alny	Royalty Liability Current RoyaltyLiabilityCurrent	40289000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	967786000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	767915000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	243101000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	261339000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	188175000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	193791000	usd
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1020776000	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1016942000	usd
CY2023Q4	alny	Royalty Liability Noncurrent RoyaltyLiabilityNoncurrent	1322248000	usd
CY2022Q4	alny	Royalty Liability Noncurrent RoyaltyLiabilityNoncurrent	1252015000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	308438000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	212580000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4050524000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3704582000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2022Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	125794000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	125794000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	123925000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	123925000	shares
CY2023Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1259000	usd
CY2022Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1240000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	6811063000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	6454540000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-23375000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-44654000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7009591000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6569349000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-220644000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-158223000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3829880000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3546359000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1828292000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1037418000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	844287000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	268216000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	140174000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	115005000	usd
CY2023	alny	Cost Of Collaboration Manufacturing And Royalties CostOfCollaborationManufacturingAndRoyalties	42190000	usd
CY2022	alny	Cost Of Collaboration Manufacturing And Royalties CostOfCollaborationManufacturingAndRoyalties	28643000	usd
CY2021	alny	Cost Of Collaboration Manufacturing And Royalties CostOfCollaborationManufacturingAndRoyalties	25139000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	883015000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	792156000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	620639000	usd
CY2023	us-gaap	Interest Expense InterestExpense	121221000	usd
CY2022	us-gaap	Interest Expense InterestExpense	155968000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	95561000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	24808000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-125682000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-134175000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2050000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-76586000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-151342000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-433517000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1126993000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6725000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4163000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	680000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-440242000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1131156000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-852824000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.52
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.52
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-9.30
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.30
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.20
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	124906000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	124906000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	121689000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	121689000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	118451000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	118451000	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-440242000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1131156000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-852824000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	11018000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-7840000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1978000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	11922000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-5274000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	11398000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	1661000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-1719000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-943000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	21279000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-11395000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	10363000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-418963000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1142551000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-842461000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1016247000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	232486000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	13631000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	168300000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	10363000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-852824000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	588203000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	263612000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	13725000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	237399000	usd
CY2022	alny	Purchases Of Capped Calls Related To Convertible Senior Notes PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes	118611000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-11395000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1131156000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-158223000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	114249000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	16428000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	225865000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	21279000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-440242000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-220644000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-440242000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1131156000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-852824000	usd
CY2023	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	54054000	usd
CY2022	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	44468000	usd
CY2021	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	47567000	usd
CY2023	alny	Amortization And Interest Accretion Related To Operating Leases AmortizationAndInterestAccretionRelatedToOperatingLeases	42977000	usd
CY2022	alny	Amortization And Interest Accretion Related To Operating Leases AmortizationAndInterestAccretionRelatedToOperatingLeases	41082000	usd
CY2021	alny	Amortization And Interest Accretion Related To Operating Leases AmortizationAndInterestAccretionRelatedToOperatingLeases	42127000	usd
CY2023	alny	Non Cash Interest Expense On Sale Of Future Royalties NonCashInterestExpenseOnSaleOfFutureRoyalties	106554000	usd
CY2022	alny	Non Cash Interest Expense On Sale Of Future Royalties NonCashInterestExpenseOnSaleOfFutureRoyalties	104200000	usd
CY2021	alny	Non Cash Interest Expense On Sale Of Future Royalties NonCashInterestExpenseOnSaleOfFutureRoyalties	116562000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	221680000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	230649000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	165717000	usd
CY2023	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-16944000	usd
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-33312000	usd
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	55695000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-76586000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023	alny	Change In Fair Value Of Liability Obligation ChangeInFairValueOfLiabilityObligation	-90997000	usd
CY2022	alny	Change In Fair Value Of Liability Obligation ChangeInFairValueOfLiabilityObligation	-94659000	usd
CY2021	alny	Change In Fair Value Of Liability Obligation ChangeInFairValueOfLiabilityObligation	-38433000	usd
CY2023	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	433000	usd
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	479000	usd
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	19243000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	87939000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	45597000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	101799000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-18367000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	34136000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	26415000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9029000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	38507000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	32093000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	80840000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	191769000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	88240000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-46502000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-43171000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-40352000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	55022000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-65911000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-50404000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	104156000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-541274000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-641693000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	62211000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	72059000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	76372000	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1823501000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1976961000	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1656114000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1553800000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2231568000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1463550000	usd
CY2023	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	58475000	usd
CY2022	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	89951000	usd
CY2021	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	41975000	usd
CY2023	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	58475000	usd
CY2022	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	98451000	usd
CY2021	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	42141000	usd
CY2023	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	4438000	usd
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	4694000	usd
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	4198000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-336350000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	169354000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-273300000	usd
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	147464000	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	259360000	usd
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	246268000	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1016111000	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2023	alny	Purchases Of Capped Calls Related To Convertible Senior Notes PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes	0	usd
CY2022	alny	Purchases Of Capped Calls Related To Convertible Senior Notes PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes	118611000	usd
CY2021	alny	Purchases Of Capped Calls Related To Convertible Senior Notes PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes	0	usd
CY2023	alny	Proceeds From Sale Of Royalties Interest ProceedsFromSaleOfRoyaltiesInterest	0	usd
CY2022	alny	Proceeds From Sale Of Royalties Interest ProceedsFromSaleOfRoyaltiesInterest	0	usd
CY2021	alny	Proceeds From Sale Of Royalties Interest ProceedsFromSaleOfRoyaltiesInterest	500000000	usd
CY2022	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	31000000	usd
CY2021	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	19600000	usd
CY2023	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	0	usd
CY2022	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	-762107000	usd
CY2021	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	500000000	usd
CY2023	alny	Payments For Transaction Costs Related To Sale Of Future Royalties And Debt PaymentsForTransactionCostsRelatedToSaleOfFutureRoyaltiesAndDebt	0	usd
CY2022	alny	Payments For Transaction Costs Related To Sale Of Future Royalties And Debt PaymentsForTransactionCostsRelatedToSaleOfFutureRoyaltiesAndDebt	0	usd
CY2021	alny	Payments For Transaction Costs Related To Sale Of Future Royalties And Debt PaymentsForTransactionCostsRelatedToSaleOfFutureRoyaltiesAndDebt	18750000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	172131000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	425753000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1247118000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6391000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-7430000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-9018000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-53672000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	46403000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	323107000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	868556000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	822153000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	499046000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	814884000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	868556000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	822153000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	32118000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	45235000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	24657000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3805000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	5213000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	13599000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	NATURE OF BUSINESS<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, we, our or us) commenced operations on June 14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on ribonucleic acid interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, global, commercial biopharmaceutical company with a deep and sustainable clinical pipeline of RNAi therapeutics for future growth and a robust, organic research engine for sustainable innovation and great potential for patient impact. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In early 2021, we launched our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy, which focuses on our planned transition to a top-tier biotech company by the end of 2025. With </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we aim to deliver transformative rare and prevalent disease medicines for patients around the world through sustainable innovation, while delivering exceptional financial performance and driving profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2023, we have five marketed products, including one collaborated product, and multiple late-stage investigational programs advancing towards potential commercialization. We currently generate worldwide product revenues from four commercialized products, ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO, primarily in the United States, or U.S., and Europe.</span></div>
CY2023Q4	alny	Number Of Products With Marketing Approval NumberOfProductsWithMarketingApproval	5	product
CY2023Q4	alny	Number Of Partnered Products NumberOfPartneredProducts	1	product
CY2023Q4	alny	Number Of Commercialized Products NumberOfCommercializedProducts	4	product
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In our consolidated financial statements, we use estimates and assumptions related to our inventory valuation and related reserves, liability related to the sale of future royalties, development derivative liability, income taxes, deferred tax asset valuation allowances, revenue recognition, research and development expenses, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentrations of Credit Risk and Significant Customers</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially expose us to concentrations of credit risk primarily consist of cash, cash equivalents and marketable securities. As of December 31, 2023 and 2022, substantially all of our cash, cash equivalents and marketable securities were invested in money market funds, certificates of deposit, commercial paper, corporate notes, U.S. government-sponsored enterprise securities and U.S. treasury securities through highly rated financial institutions. Corporate notes may also include foreign bonds denominated in U.S. dollars. Investments are restricted, in accordance with our investment policy, to a concentration limit per issuer.</span></div>
CY2023	alny	Investments Classified As Cash And Cash Equivalent Original Maturities InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities	P90D
CY2023	alny	Investment Maturity Period Minimum InvestmentMaturityPeriodMinimum	P90D
CY2023	us-gaap	Depreciation Depreciation	51600000	usd
CY2022	us-gaap	Depreciation Depreciation	39100000	usd
CY2021	us-gaap	Depreciation Depreciation	36800000	usd
CY2023Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	0	usd
CY2022Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	0	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13096000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13527000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11225000	shares
CY2022Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	208998000	usd
CY2023	alny	Valuation Allowances And Reserves Provision Related To Current Period Sales ValuationAllowancesAndReservesProvisionRelatedToCurrentPeriodSales	404992000	usd
CY2023	alny	Valuation Allowances And Reserves Sales Credit Payment Current ValuationAllowancesAndReservesSalesCreditPaymentCurrent	179020000	usd
CY2023	alny	Valuation Allowances And Reserves Sales Credit Payment Prior ValuationAllowancesAndReservesSalesCreditPaymentPrior	89029000	usd
CY2023Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	345941000	usd
CY2021Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	131316000	usd
CY2022	alny	Valuation Allowances And Reserves Provision Related To Current Period Sales ValuationAllowancesAndReservesProvisionRelatedToCurrentPeriodSales	273570000	usd
CY2022	alny	Valuation Allowances And Reserves Sales Credit Payment Current ValuationAllowancesAndReservesSalesCreditPaymentCurrent	128345000	usd
CY2022	alny	Valuation Allowances And Reserves Sales Credit Payment Prior ValuationAllowancesAndReservesSalesCreditPaymentPrior	67543000	usd
CY2022Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	208998000	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	99576000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	32342000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	290763000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	235528000	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	40500000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	55500000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1648127000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3030000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1482000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1649675000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1420603000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	119000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9589000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1411133000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	34159000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	113243000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1615516000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1297890000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1649675000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1411133000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	23346000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	22315000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	76963000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	113783000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	25123000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	25606000	usd
CY2023Q4	alny	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	125432000	usd
CY2022Q4	alny	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	161704000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	749133000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	696944000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	223076000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	173450000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	526057000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	523494000	usd
CY2023Q4	alny	Accrued Product Rebates And Discounts AccruedProductRebatesAndDiscounts	345941000	usd
CY2022Q4	alny	Accrued Product Rebates And Discounts AccruedProductRebatesAndDiscounts	208998000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	122170000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	130690000	usd
CY2023Q4	alny	Accrued Pre Clinical Clinical Trial And Manufacturing Current AccruedPreClinicalClinicalTrialAndManufacturingCurrent	111503000	usd
CY2022Q4	alny	Accrued Pre Clinical Clinical Trial And Manufacturing Current AccruedPreClinicalClinicalTrialAndManufacturingCurrent	94702000	usd
CY2023Q4	alny	Accrued Licensing And Collaboration Agreements AccruedLicensingAndCollaborationAgreements	58282000	usd
CY2022Q4	alny	Accrued Licensing And Collaboration Agreements AccruedLicensingAndCollaborationAgreements	31680000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	21155000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	19848000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	53962000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	59542000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	713013000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	545460000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	812688000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	866394000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	819975000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	2196000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	2162000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	2178000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	814884000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	868556000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	822153000	usd
CY2022	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	-5263000	usd
CY2022	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	6132000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-11395000	usd
CY2023	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	11916000	usd
CY2023	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-9363000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	21279000	usd
CY2023Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.11
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	221680000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	230649000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	165717000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	4185000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	4025000	usd
CY2021	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	3327000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	221680000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	230649000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	165717000	usd
CY2023Q4	alny	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Shares Of Common Stock Reserved For Future Issuance Under Stock Options ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsSharesOfCommonStockReservedForFutureIssuanceUnderStockOptions	18256842	shares
CY2020	alny	Employee Stock Purchase Plan Offered Period EmployeeStockPurchasePlanOfferedPeriod	P6M
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	alny	Number Of Facilities Leased NumberOfFacilitiesLeased	3	facility
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	61600000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	58600000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	59500000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	46367000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	45789000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	45359000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	20278000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	17614000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	18271000	usd
CY2023	us-gaap	Lease Cost LeaseCost	66645000	usd
CY2022	us-gaap	Lease Cost LeaseCost	63403000	usd
CY2021	us-gaap	Lease Cost LeaseCost	63630000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	46500000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	43100000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	43587000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	46369000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	40648000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	39006000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	38358000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	210073000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	418041000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	133430000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	284611000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	41510000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	243101000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	284611000	usd
CY2022Q3	alny	Number Of Patents NumberOfPatents	2	patent
CY2022Q3	alny	Number Of Lawsuits NumberOfLawsuits	1	lawsuit
CY2023Q3	alny	Number Of Disputed Terms In Lawsuit NumberOfDisputedTermsInLawsuit	3	disputed_term
CY2023Q3	alny	Number Of Disputed Terms In Lawsuit Construed NumberOfDisputedTermsInLawsuitConstrued	2	disputed_term
CY2023Q3	alny	Number Of Disputed Terms In Lawsuit NumberOfDisputedTermsInLawsuit	3	disputed_term
CY2023Q3	us-gaap	Gain Contingency Patents Found Not Infringed Upon Number GainContingencyPatentsFoundNotInfringedUponNumber	2	patent
CY2023Q2	alny	Number Of Patents NumberOfPatents	1	patent
CY2023Q4	alny	Number Of Lawsuits NumberOfLawsuits	2	lawsuit
CY2023Q3	alny	Number Of Cases NumberOfCases	1	case
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-450311000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1148604000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-794729000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	16794000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	21611000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-57415000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-433517000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1126993000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-852144000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	4022000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	293000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	3416000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	5596000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	3154000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7438000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	5596000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3447000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-713000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1433000	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-2767000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-713000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1433000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2767000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6725000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4163000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	680000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6700000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4000000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	3400000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-700000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	803221000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	803251000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	417446000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	381032000	usd
CY2023Q4	alny	Deferred Tax Assets Sale Of Future Royalties DeferredTaxAssetsSaleOfFutureRoyalties	353974000	usd
CY2022Q4	alny	Deferred Tax Assets Sale Of Future Royalties DeferredTaxAssetsSaleOfFutureRoyalties	326183000	usd
CY2023Q4	alny	Deferred Tax Assets Leasing Arrangement DeferredTaxAssetsLeasingArrangement	66558000	usd
CY2022Q4	alny	Deferred Tax Assets Leasing Arrangement DeferredTaxAssetsLeasingArrangement	67242000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	74704000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	59437000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	67150000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	52989000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	697784000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	264564000	usd
CY2023Q4	alny	Deferred Tax Assets Capitalized Research And Development Expenditures DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures	285411000	usd
CY2022Q4	alny	Deferred Tax Assets Capitalized Research And Development Expenditures DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures	206727000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	132529000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	133376000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2898777000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2294801000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	21503000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	12786000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	2277000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	5728000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	46021000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	46819000	usd
CY2023Q4	alny	Deferred Tax Liabilities Change In Accounting Method Adjustment DeferredTaxLiabilitiesChangeInAccountingMethodAdjustment	0	usd
CY2022Q4	alny	Deferred Tax Liabilities Change In Accounting Method Adjustment DeferredTaxLiabilitiesChangeInAccountingMethodAdjustment	24995000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2817395000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2193633000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	11581000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	10840000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.086
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.060
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.052
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.039
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.044
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.046
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Investment EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment	-0.067
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Investment EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment	-0.027
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Investment EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment	-0.045
CY2023	alny	Effective Income Tax Rate Reconciliation Nondeductible Expense Compensation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensation	-0.030
CY2022	alny	Effective Income Tax Rate Reconciliation Nondeductible Expense Compensation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensation	0
CY2021	alny	Effective Income Tax Rate Reconciliation Nondeductible Expense Compensation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensation	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.008
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.015
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.010
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.007
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.005
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.017
CY2023	alny	Effective Income Tax Rate Reconciliation Foreign Tax Law Enactment EffectiveIncomeTaxRateReconciliationForeignTaxLawEnactment	0.859
CY2022	alny	Effective Income Tax Rate Reconciliation Foreign Tax Law Enactment EffectiveIncomeTaxRateReconciliationForeignTaxLawEnactment	0
CY2021	alny	Effective Income Tax Rate Reconciliation Foreign Tax Law Enactment EffectiveIncomeTaxRateReconciliationForeignTaxLawEnactment	0
CY2023	alny	Effective Income Tax Rate Reconciliation Transfer Of Intellectual Property Percent EffectiveIncomeTaxRateReconciliationTransferOfIntellectualPropertyPercent	0.126
CY2022	alny	Effective Income Tax Rate Reconciliation Transfer Of Intellectual Property Percent EffectiveIncomeTaxRateReconciliationTransferOfIntellectualPropertyPercent	0
CY2021	alny	Effective Income Tax Rate Reconciliation Transfer Of Intellectual Property Percent EffectiveIncomeTaxRateReconciliationTransferOfIntellectualPropertyPercent	0.201
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.017
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.008
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001
CY2023	alny	Effective Income Tax Rate Reconciliation Revaluation Of Deferred Credits Due To Rate Change EffectiveIncomeTaxRateReconciliationRevaluationOfDeferredCreditsDueToRateChange	0.051
CY2022	alny	Effective Income Tax Rate Reconciliation Revaluation Of Deferred Credits Due To Rate Change EffectiveIncomeTaxRateReconciliationRevaluationOfDeferredCreditsDueToRateChange	-0.004
CY2021	alny	Effective Income Tax Rate Reconciliation Revaluation Of Deferred Credits Due To Rate Change EffectiveIncomeTaxRateReconciliationRevaluationOfDeferredCreditsDueToRateChange	0.011
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1.441
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.313
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.538
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.015
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	623800000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	384600000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	459300000	usd
CY2023	alny	Net Operating Loss Carryforward Percentage Of Taxable Income Available To Be Offset NetOperatingLossCarryforwardPercentageOfTaxableIncomeAvailableToBeOffset	0.80
CY2023Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	45000000	usd
CY2023	alny	Defined Benefit And Contribution Plans Contributions And Net Periodic Benefit Costs DefinedBenefitAndContributionPlansContributionsAndNetPeriodicBenefitCosts	17500000	usd
CY2022	alny	Defined Benefit And Contribution Plans Contributions And Net Periodic Benefit Costs DefinedBenefitAndContributionPlansContributionsAndNetPeriodicBenefitCosts	16500000	usd
CY2021	alny	Defined Benefit And Contribution Plans Contributions And Net Periodic Benefit Costs DefinedBenefitAndContributionPlansContributionsAndNetPeriodicBenefitCosts	13100000	usd
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001178670-24-000008-index-headers.html	Edgar Link	pending
0001178670-24-000008-index.html	Edgar Link	pending
0001178670-24-000008.txt	Edgar Link	pending
0001178670-24-000008-xbrl.zip	Edgar Link	pending
alny-20231231.htm	Edgar Link	pending
alny-20231231.xsd	Edgar Link	pending
alny-20231231_g1.jpg	Edgar Link	pending
alny-20231231_g2.jpg	Edgar Link	pending
alny-20231231_g3.jpg	Edgar Link	pending
alny2023q4exhibit211.htm	Edgar Link	pending
alny2023q4exhibit231.htm	Edgar Link	pending
alny-20231231_def.xml	Edgar Link	unprocessable
alny-20231231_lab.xml	Edgar Link	unprocessable
alny-20231231_pre.xml	Edgar Link	unprocessable
alny-20231231_htm.xml	Edgar Link	completed
alny2023q4exhibit311.htm	Edgar Link	pending
alny2023q4exhibit312.htm	Edgar Link	pending
alny2023q4exhibit321.htm	Edgar Link	pending
alny2023q4exhibit322.htm	Edgar Link	pending
alny2023q4exhibit97.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
alny-20231231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny

2024 Q1 Form 10-K Financial Statement

#000117867024000008 Filed on February 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALNY ALNYLAM PHARMACEUTICALS, INC. Stock $alny

2024 Q1 Form 10-K Financial Statement

#000117867024000008 Filed on February 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny